Michele Park joined NEA in 2021 as an investor on the Healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at Clarus Ventures (now Blackstone Life Sciences). Previously, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray. Michele received her PhD in molecular biology from Weill Cornell Graduate School of Medical Sciences, and completed her dissertation at Memorial Sloan Kettering Cancer Center. She holds a BA in molecular biology from Princeton.
Park, Michele
Michele Park, PhD
Partner, New Enterprise Associates
x
Michele Park, PhD
Partner, New Enterprise Associates
Michele Park joined NEA in 2021 as an investor on the Healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at Clarus Ventures (now Blackstone Life Sciences). Previously, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray. Michele received her PhD in molecular biology from Weill Cornell Graduate School of Medical Sciences, and completed her dissertation at Memorial Sloan Kettering Cancer Center. She holds a BA in molecular biology from Princeton.
